Jin K, Qiu S, Li J, et al. How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? Cancer Med. 2019;8:3370--3378. 10.1002/cam4.2221 31066510

Kun Jin and Shi Qiu contributed equally to this study.

**Funding information**

The authors acknowledge Ian Charles Tobias for reviewing the manuscript. Supported by the National key research and development program of China (Grant No. SQ2017YFSF090096), the Prostate Cancer Foundation Young Investigator Award 2013, the National Natural Science Foundation of China (Grant No. 81300627, 81370855, 81702536, 81770756), Programs from Science and Technology Department of Sichuan Province (Grant No. 2014JY0219 and 2017HH0063) and Young Investigator Award of Sichuan University 2017.

1. INTRODUCTION {#cam42221-sec-0005}
===============

Prostate cancer (PCa) is the second most common cancer in males, with an estimated 1.1 million confirmed cases worldwide in 2012, making up 15% deaths of all cancers diagnosed.[1](#cam42221-bib-0001){ref-type="ref"} This disease primarily encroaches on the elderly with age‐related increasing incidence rates.[2](#cam42221-bib-0002){ref-type="ref"} Autopsy studies also suggest that high‐grade intraepithelial neoplasia, the precursor of incidental PCa, are detected more easily among the old. Another European research showed that for men between 30 and 69 years of age, the prevalence of incidental PCa was 30% and sharply increased to 75% for those over 70 years of age.[3](#cam42221-bib-0003){ref-type="ref"} With the aging of population and the improvement of life expectancy, elderly people with PCa should be paid more concern.

For localized PCa, radical prostatectomy (RP) and radiotherapy (RT) are two standard interventions to decrease PCa mortality.[4](#cam42221-bib-0004){ref-type="ref"}, [5](#cam42221-bib-0005){ref-type="ref"} There is still controversy about the choice of treatment. Recently, the first randomized clinical trial, Prostate Testing for Cancer and Treatment, comparing RP, RT, and active monitoring showed that there was no significant difference of 10‐year cancer‐specific‐survival (CSS) in RP versus RT.[6](#cam42221-bib-0006){ref-type="ref"} However, several studies held the opposite opinion. Three retrospective studies indicated that people received RP was superior to RT in terms of biochemical recurrence, metastasis‐free survival, and CSS.[7](#cam42221-bib-0007){ref-type="ref"}, [8](#cam42221-bib-0008){ref-type="ref"}, [9](#cam42221-bib-0009){ref-type="ref"} These studies contained patients of all T stages and none of these focused on the elderly.

In consideration of worse physical conditions, advanced stage and higher pathological grade compared with the younger,[10](#cam42221-bib-0010){ref-type="ref"} the outcome of RP or RT among old people may differ from others. Two observational studies discussing the benefit of local treatment (RP or RT) for men ≥70 years of age of low risk and for men ≥75 years of age were performed.[11](#cam42221-bib-0011){ref-type="ref"}, [12](#cam42221-bib-0012){ref-type="ref"} Despite adjustment for covariates to control measured confounders, there remains residual confounding comparing RT with RP. In view of this, we aimed to provide risk estimates to inform contemporary treatment decision for PCa men aged ≥75 years.

2. METHOD {#cam42221-sec-0006}
=========

2.1. Study populations {#cam42221-sec-0007}
----------------------

In the Surveillance Epidemiology and End Results (SEER) database (2004‐2015), old men diagnosed with histological adenocarcinoma of the prostate \[International Classification of Disease for Oncology (ICD‐O‐3) code 8140 of the prostate (site code C61.9)\] over 75 years of age were selected in our research. Old people with T1 stage PCa mostly received RT, causing huge bias in the analysis. As a result, our research only included individuals with T2 stage. Further inclusion/exclusion criteria are depicted in Figure [1](#cam42221-fig-0001){ref-type="fig"}. Our study consisted of 10 563 patients in final, who were stratified based on different therapy type: RT group versus RP group. The total available covariates were listed in Table [1](#cam42221-tbl-0001){ref-type="table"}.

![Flowchart of the patients selection](CAM4-8-3370-g001){#cam42221-fig-0001}

###### 

Baseline characteristics of 10 563 patients who received RT versus RP

                                RT (N = 8447)       RP (N = 2116)     *P* value
  ----------------------------- ------------------- ----------------- -----------
  Age                           78.593 ± 3.184      76.894 ± 2.511    \<0.001
  PSA                           116.632 ± 137.769   74.947 ± 88.731   \<0.001
  Marital status                                                      \<0.001
  Married                       5878 (69.587%)      1650 (77.977%)     
  Single                        443 (5.244%)        105 (4.962%)       
  Divorced/widowed              1265 (14.976%)      252 (11.909%)      
  Unknown                       861 (10.193%)       109 (5.151%)       
  Year of diagnosis                                                   \<0.001
  2004                          851 (10.075%)       163 (7.703%)       
  2005                          798 (9.447%)        131 (6.191%)       
  2006                          821 (9.719%)        155 (7.325%)       
  2007                          851 (10.075%)       200 (9.452%)       
  2008                          753 (8.914%)        161 (7.609%)       
  2009                          725 (8.583%)        188 (8.885%)       
  2010                          742 (8.784%)        221 (10.444%)      
  2011                          729 (8.630%)        212 (10.019%)      
  2012                          587 (6.949%)        158 (7.467%)       
  2013                          514 (6.085%)        186 (8.790%)       
  2014                          505 (5.978%)        154 (7.278%)       
  2015                          571 (6.760%)        187 (8.837%)       
  Race                                                                \<0.001
  White                         7014 (83.035%)      1834 (86.673%)     
  Black                         661 (7.825%)        111 (5.246%)       
  Other                         618 (7.316%)        153 (7.231%)       
  Unknown                       154 (1.823%)        18 (0.851%)        
  GS                                                                  \<0.001
  ≤6                            1195 (14.147%)      343 (16.210%)      
  7                             2009 (23.784%)      513 (24.244%)      
  ≥8                            1324 (15.674%)      111 (5.246%)       
  Unknown                       3919 (46.395%)      1149 (54.301%)     
  Region                                                              \<0.001
  East                          2696 (31.917%)      444 (20.983%)      
  Pacific                       4233 (50.112%)      1387 (65.548%)     
  North                         1216 (14.396%)      133 (6.285%)       
  Other(Alaska and Southwest)   302 (3.575%)        152 (7.183%)       

Abbreviations: GS, Gleason score; PSA, prostate specific antigen; RP, radical prostatectomy; RT, radiation therapy.
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2.2. Endpoint {#cam42221-sec-0008}
-------------

Our main endpoint included: cancer‐specific mortality (CSM) defined as death caused by prostate malignancy (SEER code 28010); overall mortality (OM) defined as deaths from any reason reported by the SEER database. Survival time was defined as the duration from initial diagnosis to death from any cause or last follow‐up.

2.3. Statistical analysis {#cam42221-sec-0009}
-------------------------

Firstly, we assessed the distribution of baseline characteristics with the use of a two‐sample t test and a chi‐square test to compare continuous and categorical variables, respectively. Data were presented as mean ± SD for continuous variables and as frequency (%) for categorical variables.

Secondly, a multivariable Cox proportional hazard model was used for analyses of OM and CSM after adjusting race, age, marital status, Gleason Score (GS), and prostate specific antigen (PSA).[13](#cam42221-bib-0013){ref-type="ref"}

Thirdly, in consideration of baseline characteristics affecting the option of using different treatment methods, propensity score matching (PSM) (ratio 1:1, with a caliper set of 0.05) was performed to ensure that both the RT group and the RP group had similar baseline characteristics with the use of logistic regression to adjust for between‐group differences.[14](#cam42221-bib-0014){ref-type="ref"} The matching was conducted based on nearest‐neighbor matching principle. The matched process was considered as balanced with a *P* value \>0.05.

Fourthly, considering the selection bias between patients who received RT versus RP, we additionally used an instrument variate (IVA) to calculate the unmeasured confounders. We selected yearly regional utilization rate as IVA to perform a two‐stage residual inclusion analysis.[15](#cam42221-bib-0015){ref-type="ref"}, [16](#cam42221-bib-0016){ref-type="ref"} This IVA was previously used in the literature [17](#cam42221-bib-0017){ref-type="ref"}, [18](#cam42221-bib-0018){ref-type="ref"}, [19](#cam42221-bib-0019){ref-type="ref"}, [20](#cam42221-bib-0020){ref-type="ref"} and calculated for each of the four American regions as follows:$$\frac{\text{RP\ cases/region/yr}}{{(\text{RP\ cases/region/yr})} + \left( \text{RT\ cases/region/yr} \right)}$$

We calculated the F‐statistic to confirm its correlation with the option of therapy. And the residual, defined as the observed minus the predicted probability of receiving RP, was calculated. The second IVA assumption was verified that without the use of IVA, the correlation between exposure and outcome cannot be formally tested. Another multivariate Cox proportional hazard model including all covariates and residual was presented.

Sensitivity analyses were performed: (a) The analysis of CSM after adjusting propensity scores; (b) two additional models with inverse probability of treatment weighing (IPTW) and standardized mortality ratio weighting (SMRW) using the propensity score to evaluate the relationship between treatment types and outcomes including all eligible patients (entire cohort); (c) the analysis of CSM stratified by propensity scores; and (d) Competing‐risks regression assessing the CSM.

All analyses were performed with the statistical software packages R (<http://www.R-project.org>, The R Foundation) and EmpowerStats (<http://www.empowerstats.com>, X&Y Solutions, Inc, Boston, MA). A *P* value \<0.05 was considered statistically significant.

3. RESULTS {#cam42221-sec-0010}
==========

A total of 10,563 elderly men (age ≥75 years) were identified in our study; 8447 patients received RT while 2116 received RP. Details of the baseline characteristics stratified according to RT versus RP were reported in Table [1](#cam42221-tbl-0001){ref-type="table"}. The two treatment groups differed significantly in regard to most clinical indicators. Results of the multivariate Cox proportional hazard regression showed that RP could reduce more risks of OM and CSM after adjusted for race, age, marital status, GS and PSA (hazard ratio \[HR\]=0.54, 95% CI = 0.47‐0.62, *P* \< 0.001 and HR = 0.30, 95% CI = 0.20‐0.45, *P* \< 0.001, respectively). From the Kaplan‐Meier survival curve, the significant survival benefits were observed in the comparison of RP and RT (Figure [2](#cam42221-fig-0002){ref-type="fig"}).

![Subgroup analyses of CSM and OM (RT vs RP)](CAM4-8-3370-g002){#cam42221-fig-0002}

Following PSM, there were 2152 individuals in each treatment group (Table [2](#cam42221-tbl-0002){ref-type="table"}). The cox model after matching indicated that RP was still superior to RT (OM: HR = 0.53, 95% CI = 0.46‐0.62, *P* \< 0.001; CSM: HR = 0.27, 95% CI = 0.17‐0.43, *P* \< 0.001) (Table [3](#cam42221-tbl-0003){ref-type="table"}). In consideration of the differences after the matching, another cox model adjusted for propensity scores was conducted (Supplement Table [S2](#cam42221-sup-0001){ref-type="supplementary-material"}). Moreover, the results of the sensitivity analyses showed similar outcome (Supplement Table [S3](#cam42221-sup-0001){ref-type="supplementary-material"}). In the IVA‐adjusted model, the effect of treatment changed slightly (OM: HR = 0.65, 95% CI = 0.54‐0.78, *P* \< 0.001; CSM: HR = 0.21, 95% CI = 0.12‐0.37, *P* \< 0.001).

###### 

Baseline characteristics of 4304 patients after propensity score match according to treatment

                                RT (N = 2152)   RP (N = 2152)   *P* value
  ----------------------------- --------------- --------------- -----------
  Age                           76.88 ± 2.30    76.89 ± 2.51    0.8791
  PSA                           79.51 ± 92.88   75.11 ± 88.92   0.1121
  Year of diagnosis                                             \<0.0001
  2004                          226 (10.50%)    165 (7.67%)      
  2005                          186 (8.60%)     132 (6.13%)      
  2006                          189 (8.78%)     156 (7.25)       
  2007                          195 (9.06%)     205 (9.53%)      
  2008                          204 (9.48%)     166 (7.71%)      
  2009                          189 (8.78%)     190 (8.83%)      
  2010                          200 (9.29%)     222 (10.32%)     
  2011                          200 (9.29%)     215 (9.99)       
  2012                          139 (6.46%)     161 (7.48%)      
  2013                          148 (6.88%)     193 (8.97%)      
  2014                          127 (5.90%)     158 (7.34%)      
  2015                          149 (6.92%)     189 (8.78%)      
  Marital status                                                0.0604
  Married                       1728 (80.3%)    1679 (78%)       
  Single                        103 (4.8%)      106 (4.9%)       
  Divorced/widowed              202 (9.4%)      256 (11.9%)      
  Unknown                       119 (5.5%)      111 (5.2%)       
  Race                                                          0.0083
  White                         1892 (87.9%)    1867 (86.8%)     
  Black                         137 (6.4%)      113 (5.3%)       
  Other                         105 (4.9%)      154 (7.2%)       
  Unknown                       18 (0.8%)       18 (0.8%)        
  GS                                                            \<0.0001
  ≤6                            324 (15.1%)     346 (16.1%)      
  7                             487 (22.6%)     522 (24.3%)      
  ≥8                            277 (12.9%)     115 (5.3%)       
  Unknown                       1064 (49.4%)    1169 (54.3%)     
  Region                                                        \<0.0001
  East                          744 (34.6%)     452 (21%)        
  Pacific                       1006 (46.7%)    1413 (65.7%)     
  North                         319 (14.8%)     134 (6.2%)       
  Other(Alaska and Southwest)   83 (3.9%)       153 (7.1%)       

Abbreviations: GS, Gleason score; PSA, prostate specific antigen; RT, radiation therapy; RP, radical prostatectomy.

John Wiley & Sons, Ltd

###### 

Multivariate cox regression analyses for OS and CSM in the total cohort and matched population

  Outcome   Treatment   Non‐adjusted model   Adjusted model      PSM model           IVA‐adjusted model
  --------- ----------- -------------------- ------------------- ------------------- --------------------
  OM        RT          1.0                  1.0                 1.0                 1.0
            RP          0.42 (0.37, 0.48)    0.54 (0.47, 0.62)   0.53 (0.46, 0.62)   0.65 (0.54, 0.78)
  CSM       RT          1.0                  1.0                 1.0                 1.0
            RP          0.21 (0.14, 0.32)    0.30 (0.20, 0.45)   0.27 (0.17, 0.43)   0.21 (0.12, 0.37)

Adjusted model: adjusted for race, age, marital status, Gleason score (GS) and prostate specific antigen (PSA). Propensity score matching (PSM) model: matched according to race, age, marital status, GS and PSA. Instrument variate (IV) adjusted model: adjusted for race, age, marital status, GS and PSA and residual

Abbreviations: CSM, cancer specific mortality; OM, overall mortality.

John Wiley & Sons, Ltd

In the subgroup analyses (Figure [3](#cam42221-fig-0003){ref-type="fig"}), no significant interaction was observed between the effect of OS and marital status or race (P value of interaction, 0.24 and 0.22, respectively). We did observe a larger magnitude of association between GS and OS (P value for interaction, 0.02). The results indicated that for patients with GS = 7, those received RP obtained the highest risk decline for overall death (HR = 0.41, 95% CI = 0.32‐0.52). And no significant interaction was observed between the effect of OS and age or PSA (*P* value of interaction, 0.07 and 0.24, respectively). In the subgroup analyses of CSM, a significant relationship between CSM and age was observed (P value for interaction, 0.02), indicating that for patients with younger age, those received RP obtained the highest risk decline for CSM (HR = 0.11, 95% CI = 0.01‐0.52). Other covariates such as marital status, race, GS, and PSA showed no significant interaction effects (*P* value of interaction, 0.53, 0.95, 0.27 and 0.45, respectively).

![Kaplan‐Meier survival curve of CSM and OM (RT vs RP)](CAM4-8-3370-g003){#cam42221-fig-0003}

4. DISCUSSION {#cam42221-sec-0011}
=============

Among PCa people with the age ≥75, it still remains uncertain regarding the efficacy of modalities of local treatment. Several studies focusing on the role of RT or RP have excluded the old individuals.[6](#cam42221-bib-0006){ref-type="ref"}, [21](#cam42221-bib-0021){ref-type="ref"}, [22](#cam42221-bib-0022){ref-type="ref"} Based on the EAU guideline, both RT and RP are all radical treatments for patients with localized PCa. However, researches about old people aged over 75 years are lacking, doctors should take the poor conditions of the elderly into account when making the decision. Based on these considerations, we attempted to assess the efficacy of RT versus RP as the primary therapy in a contemporary cohort of US men diagnosed with cT2 PCa. We observed that, for PCa people aged over 75 years, those received RP showed less likeliness to die compared with those received RT. Besides, the patients in the RP group had lower risks of CSM than their counterparts who received RT.

In one observational study targeted to Swedish PCa patients of all ages and all clinical stages, men treated with RT are more likely to develop cancer‐specific death for the low‐ and intermediate‐risk cancer.[23](#cam42221-bib-0023){ref-type="ref"} In another observational study from SEER database, men treated with RP have higher cancer‐specific‐survival rate after metastasis than those treated with RT. The difference appears more significant among intermediate‐ and high‐risk cancer. [24](#cam42221-bib-0024){ref-type="ref"} Although people with the age ≥75 were included in these studies, subgroup analyses of age and clinical T stage were not performed. According to Kevin R. Rice, et al, for low risk PCa in men ≥70 years of age, no significance was found in the comparison between RP and RT.[11](#cam42221-bib-0011){ref-type="ref"} Although baseline characteristics are different in the two groups, interestingly, the results from locally weighed regression (IPTW and SMRW models) suggested variations between the two therapies had little effect on the clinical outcome.

For lack of any published or ongoing randomized controlled trial testing the choice of curing cT2 PCa for men aged over 75 years, our observational study could provide important reference to the decision‐maker. Even more noteworthy is that our comprehensive assessment overcomes the limited ability to account for unmeasured confounders contrast to previous reports.

There are still some limitations of our study. Despite our efforts to overcome the selection bias and confounders in statistical analysis to the maximum extent, there are still indicators disturbing the accuracy of our results, which is natural in any observational study. Still another limitation is the lack of data about the details of androgen deprivation therapy using, which affects the oncological outcome. Last, although we believe the treatments accord with contemporary standards, treatments may be different due to constant evolution. In particular, the surgical procedures of RP and the radiation dose of RT would be considered inadequate by current standards.

5. CONCLUSION {#cam42221-sec-0012}
=============

Patients over 75 years of age with cT2 stage will obtain more benefit from RP compared with RT, especially for patients with GS = 7 and younger age. These findings may facilitate counseling regarding the standard treatments for localized cT2 PCa among old people.
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